24 
(8) appropriate additional recommendations for the conduct 
of recombinant DXA acivities particularly with respect to the 
best approaches for assuring the safest and most appropriate 
applications and uses of recombinant DXA and the appropriate 
role of assessment of risk-benefit criteria in these determinations; 
(fi) a determination of the status and extent of recombinant 
DXA activities conducted in exempted areas in the United States 
and in areas outside the United States, and an analysis of the 
nature of regulation in other countries : 
(10) a summary of the Commission's decisions with respect to 
the facilities which have been licensed and the terms and condi- 
tions attached thereto ; and 
(11) a summary of actions taken to accomplish the purposes of 
the Recombinant DXA Safety Regulation Act. the nature of the 
difficulties encountered in enforcement, the number and nature of 
penalties imposed during the preceding year and an evaluation 
of their adequacy as deterrants to future violations, areas of re- 
combinant DXA activity outside this part which might pose a 
danger to researchers, the public or the environment, and any other 
enforcement, administrative, or jurisdictional problems or ques- 
tions encountered by the Commission in carrying out its duties 
under this part and a recommendation for administrative or legis- 
lative actions which would correct such problems. 
LICENSE REVOCATION’. SUSPENSION OR LIMITATION 
Section 1505 of bill S. 1217 outlines the conditions for license revoca- 
tion. suspension or limitation. If at a facility the Commission finds that 
a person authorized to engage in Recombinant DXA activities lias 
knowingly, wifiingfully. or negligently — 
1. maintained or submitted any required records, or data which 
contain any false or misleading information, 
2. engaged or attempted to engage or represent himself as en- 
titled to perform any Recombinant DXA activities in a manner 
not authorized by the license. 
3. failed to register a Recombinant DXA project, prior to the 
commencement of the project in accordance with section ISIS. 
4. failed to comply with a request of the Conunission for any 
information or materials the Commission finds necessary to deter- 
mine the facility’s continued eligibility for a license or to evaluate 
the possible health or environmental etf'ects of Recombinant DXA 
activities, or 
5. failed to comply with the request of the Commission or in- 
spector. or other authorized agent of the Conunission to carry out 
an inspection of the facility or its operations. 
The Commission shall revoke the license of the facility for the re- 
mainder of its term and may make the facility ineligible for a license 
as a period of time as the Commission may determine. 
If the Commission finds that a person authorized to engage in 
Recombinant DXA activities in connection with a faeilitv has know- 
ingly. willingfully or negligently — 
1. failed to comply with any of the terms or conditions of the 
license, or 
[ 764 ] 
